干扰素αlb治疗82例慢性乙型肝炎临床疗效观察

The clinical effect of interferon alpha-1b(α1b) in treating 82 patients of chronic hepatitis B

[目的]观察干扰素α1b治疗慢性乙型肝炎的临床疗效。[方法]慢性乙型肝炎患者分为两组,治疗组82例,男性68例,女性14例,平均年龄为(31±9)岁。应用干扰素α1b治疗,每次300万单位,肌肉注射,隔日一次,疗程4个月。对照组32例,男性21例,女性11例,平均年龄为(35±12)岁,给予一般保肝药物治疗,疗程4个月。[结果]干扰素α1b治疗组的HBeAg和HBV DNA阳转率(分别为51.5%和49.3%)明显高于对照组(分别为6.5%和8%)。[结论]干扰素α1b是一种治疗慢性乙型肝炎的有效抗病素药物。

[ Objective] To observe the clinical effect of interferon α1b in treating patients with chronic hepatitis B. [ Methods] The patients with chronic hepatitis B were divided into two groups. The treatment group of 82 patients （ M 68, F 14, age 35 a ± 9a） received interferon α1b 3 MU, im, every other day for 4 months. The control group of 32 patients （ M 21, F 11, age 35a ± 12a） received drugs protecting liver for 4 months. [ Results] The seroversal rate of HBeAg and HBV DNA in the treatment group were 51.5% . 49.3% respectively, which was much better than that （6.5% , 8% respectively） in the control group （ P 〈 0. 001 ）. [ Conclusion ] Interferon α1b is an effective antiviral drug in treating chronic hepatitis B.